Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference

January 22, 2024

https://www.globenewswire.com/news-release/2024/01/22/2812972/0/en/Taysha-Gene-Therapies-Announces-Poster-Presentation-on-TSHA-102-in-Rett-Syndrome-at-Upcoming-British-Paediatric-Neurology-Association-2024-Annual-Conference.html

DALLAS, Jan. 22, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that it will present clinical data on its TSHA-102 program in evaluation for Rett syndrome during an oral poster presentation at the upcoming British Paediatric Neurology Association (BPNA) 2024 Annual Conference, taking place in Bristol, England from January 24-26, 2024.

Read more at globenewswire.com

Related news for (TSHA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.